基于酸盐的智能注射水凝的设计和表征,用于改善抗毒品的持续释放
Maryam Aftab1, Fatima Javed2, Sajjad Haider3
1Department of Biosciences, COMSATS University, Park Road, Islamabad 45520, Pakistan.
Pharmaceuticals (Basel, Switzerland)
|June 27, 2024
概括
使用奇托桑和瓜尔的新注射水凝可以延长抗毒药的释放时间,可能改善药物成治疗的坚持性,并降低复发率.
科学领域:
- 生物材料科学 生物材料科学
- 聚合物化学 聚合物化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 持续的药物释放配方对于提高药物成的治疗坚持至关重要.
- 现有的配方提供有限的释放时间,需要改进的输送系统.
- 可以注射的水凝为长时间的药物输送提供了一个有希望的平台.
研究的目的:
- 开发和描述基于素 (CS) 和瓜尔 (GG) 的新型注射水凝 (IHs),用于持续释放抗毒药物.
- 为了评估低分子量 (LMW) 和高分子量 (HMW) 基托桑配方的IHs的物理化学特性和药物释放概况.
- 评估这些IHs在改善药物成治疗坚持治疗方面的潜力.
主要方法:
- 通过将LMW-CS/HMW-CS与GG结合并与二基二酸盐交叉连接来配制IHs.
- 使用FT-IR,TGA,SEM,风病学,胀和生物降解研究进行了表征.
- 在56天的时间里,纳尔德 (NTX) 和二硫 (DSF) 装入PBS和乙醇的IH和体外释放研究中.
主要成果:
- HMW-CS IH表现出优越的性能,包括高交叉连接,热稳定性,机械强度,膨胀和低生物降解.
- 药物释放研究表明,持续释放的概况超过56天.
- 药物释放动力学遵循PBS和特定乙醇度的非Fickian模型,表明复杂的释放机制.
结论:
- 开发的HMW-CS IH配方显示出持续提供抗毒药物的巨大潜力.
- 这些先进的水凝系统可以提高治疗的坚持性,并降低吸毒成患者的复发率.
- 对体内表现的进一步研究是有必要的,以验证治疗疗效.
更多相关视频
相关概念视频
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
336
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
336
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
139
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
139
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
184
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
184
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
165
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
165
01:26Oral Drug Delivery Systems: Continuous-Release Systems
319
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
319
01:11Oral Drug Delivery Systems: Delayed-Release Systems
228
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
228